HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gómez, C. E. Articles by Esteban, M. Search for Related Content PubMed PubMed Citation Articles by Gómez, C. E. Articles by Esteban, M. Agricola Articles by Gómez, C. E. Articles by Esteban, M.

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice

Carmen Elena Gómez^1,

José Luis Nájera^1,

¹ Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
² Division of Hepatology and Gene Therapy, Center for Investigation in Applied Medicine (CIMA), University of Navarra, 31080 Pamplona, Spain

Correspondence
Mariano Esteban
mesteban{at}cnb.uam.es

Recombinant vaccinia viruses based on the attenuated NYVAC and MVA strains are promising vaccine candidates against a broad spectrum of diseases. Whilst these vectors are safe and immunogenic in animals and humans, little is known about their comparative behaviour in vivo. In this investigation, a head-to-head analysis was carried out of virus dissemination in mice inoculated by the mucosal or systemic route with replication-competent (WRluc) and attenuated recombinant (MVAluc and NYVACluc) viruses expressing the luciferase gene. Bioluminescence imaging showed that, in contrast to WRluc, the attenuated recombinants expressed the reporter gene transiently, with MVAluc expression limited to the first 24 h and NYVACluc giving a longer signal, up to 72 h post-infection, for most of the routes assayed. Moreover, luciferase levels in MVAluc-infected tissues peaked earlier than those in tissues infected by NYVACluc. These findings may be of immunological relevance when these vectors are used as recombinant vaccines.

These authors contributed equally to this work.

This article has been cited by other articles:

				M. Zaitseva, S. M. Kapnick, J. Scott, L. R. King, J. Manischewitz, L. Sirota, S. Kodihalli, and H. Golding Application of Bioluminescence Imaging to the Prediction of Lethality in Vaccinia Virus-Infected Mice J. Virol., October 15, 2009; 83(20): 10437 - 10447. [Abstract] [Full Text] [PDF]

				P. Mooij, S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, et al. Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates J. Virol., March 15, 2008; 82(6): 2975 - 2988. [Abstract] [Full Text] [PDF]